<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02246257</url>
  </required_header>
  <id_info>
    <org_study_id>OdenseUH</org_study_id>
    <nct_id>NCT02246257</nct_id>
  </id_info>
  <brief_title>Early Rheumatoid Arthritis COR Intervention</brief_title>
  <acronym>ERACORI</acronym>
  <official_title>Multifactorial Intervention to Prevent Cardiovascular Disease in Patients With Early Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MD, PhD, Annemarie Lyng Svensson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of our present study is to evaluate the effect of a targeted, intensified,
      multidimensional intervention compared to conventional treatment of modifiable risk factors
      for CVD in patients with early RA. The primary endpoint, a composite of death from
      cardiovascular causes, non-fatal MI, non-fatal stroke and re-vascularisation, will be
      assessed after 5years' follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective randomised open, blinded endpoint trial with balanced
      randomisation (1:1) conducted in seven outpatient clinics in Denmark. Follow-up visits for
      patients in the intervention group are scheduled to occur at baseline and then after 2, 4 and
      12 weeks and thereafter every third month for 5 years after randomisation. The control group
      will be monitored for RA disease activity and comorbidity after 2, 4 weeks, 12 weeks and
      thereafter following national guidelines for RA. Prevention of CVD risk factors in the
      control group will be treated in general practice according to national guidelines for
      diabetes (2011), hypertension (2009) and CVD (2013).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Major Cardiac Event (death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke and cardiac revascularization)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Days from randomization to the first of cardiac event. If no event, censoring occurs at earliest of termination date or efficacy cut-off date of 31 December 2020. Events will be adjudicated by an endpoint committee. Kaplan-Meier estimate of the mean.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Death Due to Any Cause</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Days from randomization to death. If no death then censoring occurs at earliest of termination date or efficacy cutoff date of 31 Dec 2020. Kaplan-Meier estimate of the mean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Non-cardiovascular Death</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Days from randomization to death from a non-cardiovascular cause. If no event, then censoring occurs at earliest of termination date or efficacy cutoff date of 31 Dec 2020. Events will be adjudicated by an endpoint committee. Kaplan-Meier estimate of the mean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Serious Adverse Event (hospitalizations)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Time from randomization to the first venous thromboembolic event. Kaplan-Meier estimate of the mean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients having a treatment success</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>LDL cholesterol &lt; 2.5 mmol/l
HbA1c &lt; 48 mmol/mol (HbA1c &lt; 6.5%),
Blood pressure &lt; 140/90 mmHg for non-diabetic patients and &lt; 130/80 mm Hg for diabetic patients and normoalbuminuria (urinary albumin creatinine ratio &lt; 30 mg/g) after 1-year of follow-up this in agreement with present national guidelines, which will be adjusted accordingly to any future changes in the respective national guidelines.
Low RA disease activity DAS28-CRP &lt; 3.2 and DAS28-CRP &lt; 2.6 at 12, 24 and 60 months. Furthermore, all to hospitalisations will be adjudicated by the event committee</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In the intervention group all patients will receive statins according to national guidelines. Stepwise introduction of pharmacological therapy targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria and behaviour modification will be controlled by the project team in an outpatient rheumatology department.
Hyperlipidaemia: LDL &gt; 2.5 is treated with 40 mg Simvastatin; Hypertension: BT &gt; 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT &gt; 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio &gt; 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C &gt; 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In the control group patients will be refered to general practice for pharmacological therapy according to national guidelines targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria.
Hyperlipidaemia: LDL &gt; 2.5 is treated with 40 mg Simvastatin; Hypertension: BT &gt; 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT &gt; 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio &gt; 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C &gt; 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>LDL &gt; 2.5 is treated with 40 mg</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Hyperlipidaemia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>BT &gt; 140/90 mmHg treated with 50 mg OD</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Hypertension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>DM BT &gt; 130/80 mmHg treated with 50 mg OD</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Diabetes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Microalbuminuria (urinary albumin creatinin ratio &gt; 30 mg) treated with 100 mg OD</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Microalbuminuria</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>HBA1C &gt; 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Hyperglycaemia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Outpatient rheumatology department</intervention_name>
    <description>(4 times yearly)</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Refered to general practice</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RA according to the revised American College of Rheumatology (ACR) 2010 criteria and
             plasma LDL &gt; 2.5mmol/l.

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation

          -  Ongoing/previous DMARD therapy

          -  Ongoing/previous steorid therapy

          -  Contraindication to any of the trial drugs

          -  Current infection with parvovirus B19, hepatitis B, hepatitis C or human immune
             deficiency virus. Previous report of hospitalisation for myocardial ischaemia defined
             as follows: a) non-fatal myocardial infarction (MI) defined according to national and
             international guidelines. b) Acute coronary syndrome (ACS) including acute ischaemic
             symptoms with possible biomarker changes or elctrocardiographic changes that to not
             meet the criteria for MI, c) angina pectoris, d) revascularisation (percutaneous
             coronary intervention (PCI) or coronary artery bypass grafting (CABG).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torkell J Ellingsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annemarie L Svensson, MD, PhD</last_name>
    <phone>+45 28 555 126</phone>
    <email>lyng.annemarie@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Torkell J Ellingsen, MD, PhD</last_name>
    <phone>+45 6541 1814</phone>
    <email>torkell.ellingsen@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Rheumathology, Frederiksberg and Bispebjerg univeristy Hospital</name>
      <address>
        <city>Frederiksberg</city>
        <state>Region Of Copenhagen</state>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annemarie Lyng Svesson, MD, PhD</last_name>
      <phone>004528555126</phone>
      <email>lyng.annemarie@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Torkell J Ellingsen, MD, PhD, Professor</last_name>
      <phone>004565413523</phone>
      <email>torkell.ellingsen@rsyd.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2014</study_first_posted>
  <last_update_submitted>April 15, 2018</last_update_submitted>
  <last_update_submitted_qc>April 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>MD, PhD, Annemarie Lyng Svensson</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

